--- title: "Goldman Sachs gives Pharmaron a \"Buy\" rating with a target price of 30.7 yuan" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/278817298.md" description: "Goldman Sachs gives Pharmaron a \"Buy\" rating with a target price of 30.7 yuan. Pharmaron has reached a collaboration with Eli Lilly, which will invest 200 million USD to support the supply of Orforglipron in China. Eli Lilly plans to invest 3 billion USD over the next decade to expand its supply chain capacity in China. Goldman Sachs believes this collaboration reflects Eli Lilly's confidence in the Chinese market and expects Pharmaron to receive a positive market response" datetime: "2026-03-12T03:45:06.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278817298.md) - [en](https://longbridge.com/en/news/278817298.md) - [zh-HK](https://longbridge.com/zh-HK/news/278817298.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/278817298.md) | [English](https://longbridge.com/en/news/278817298.md) # Goldman Sachs gives Pharmaron a "Buy" rating with a target price of 30.7 yuan Goldman Sachs published a research report indicating that Pharmaron (03759.HK) has reached a cooperation agreement with Eli Lilly (LLY.US) to support the local supply of Orforglipron in China. Eli Lilly is expected to invest $200 million in Pharmaron to support its technological capability building, with the potential to further expand the scope of cooperation as the project progresses. At the same time, Eli Lilly plans to cumulatively invest $3 billion over the next decade to comprehensively expand its supply chain capacity in China with several local companies, aiming to establish a localized manufacturing and supply system for oral solid dosage forms, particularly focusing on building production capacity for Orforglipron. Eli Lilly China has submitted a listing application for Orforglipron for the treatment of type 2 diabetes and obesity to the National Medical Products Administration by the end of 2025. The firm believes that Eli Lilly's commitment to local capital expenditure reflects its confidence in the long-term growth potential of the obesity drug market in China. Regarding the fundamental impact on Pharmaron, a more substantial assessment of the earnings contribution and strategic significance will depend on further disclosures. The firm expects management to provide more details in the upcoming earnings conference call, including the cooperation model, potential order scale, and the commercialization trajectory of Orforglipron after approval in China. Nevertheless, the firm anticipates that Pharmaron will receive a positive market response, as this partnership emphasizes Eli Lilly's recognition of Pharmaron as a qualified partner within the local GLP-1 supply chain. The firm has assigned Pharmaron a "Buy" rating for its Hong Kong stock, with a target price of HKD 30.7; it has given Pharmaron (300759.SZ) a "Neutral" rating for its A shares, with a target price of RMB 38 ### 相關股票 - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-HK/quote/588250.CN.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-HK/quote/159506.CN.md) - [Hwabao WP CSI Pharmaceuticals ETF (562050.CN)](https://longbridge.com/zh-HK/quote/562050.CN.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-HK/quote/159859.CN.md) - [PHARMARON (03759.HK)](https://longbridge.com/zh-HK/quote/03759.HK.md) - [Pharmaron (300759.CN)](https://longbridge.com/zh-HK/quote/300759.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md) - [Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII) (520500.CN)](https://longbridge.com/zh-HK/quote/520500.CN.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-HK/quote/560600.CN.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-HK/quote/510660.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md) ## 相關資訊與研究 - [Biocytogen and Sihuan partner to advance new therapeutics for weight loss](https://longbridge.com/zh-HK/news/281501537.md) - [RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial](https://longbridge.com/zh-HK/news/281458440.md) - [Annovis Bio Director Purchased Shares Worth Over $1.4M](https://longbridge.com/zh-HK/news/281662341.md) - [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/zh-HK/news/281325910.md) - [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/zh-HK/news/281231901.md)